Simplify Logo

Full-Time

Director/Senior Director

Clinical Pharmacology

Posted on 3/15/2024

Tango Therapeutics

Tango Therapeutics

51-200 employees

Develops targeted cancer therapies using synthetic lethality

Biotechnology
Healthcare

Senior, Expert

Boston, MA, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • PhD or PharmD in clinical pharmacology, pharmacometrics, or related discipline with at least 7-10 years’ experience in the pharmaceutical and/or biotech industry
  • Experience with small molecule drug development in oncology preferred (required for consideration at the Senior Director level)
  • In-depth knowledge of drug metabolism, pharmacokinetics, biopharmaceutics, drug-drug interactions, and translational science
  • Experience with health authority interactions and regulatory filings
  • Experience as lead or contributing clinical pharmacologist on a successful NDA submission preferred (required for consideration at the Senior Director level)
  • Familiar with GLP, GCP, and ICH requirements
  • Hands-on experience in population pharmacokinetics/pharmacodynamics, and other modeling and simulation approaches preferred (required for consideration at the Senior Director level)
Responsibilities
  • Design and implementation of clinical pharmacology aspects of patient trials and NDA-enabling clinical pharmacology studies
  • Collaborate with clinical development teams to optimize patient trial design and execution
  • Establish and maintain relationships with internal business partners, consultants, and CROs

Tango Therapeutics develops targeted cancer treatments using the principle of synthetic lethality, which allows them to design drugs that kill cancer cells while leaving healthy cells unharmed. Their approach focuses on the interaction between genes, where the loss of both genes leads to cell death, but the loss of just one does not. This method enables them to create more effective therapies for cancer patients. Tango operates in the oncology market, primarily serving healthcare providers and pharmaceutical companies. They collaborate with larger firms, like Gilead Sciences, to co-develop therapies, which helps them secure funding and speed up the development process. Their goal is to bring next-generation targeted immunotherapies to market, supported by a strong team and strategic partnerships.

Company Stage

IPO

Total Funding

$537M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

2%

1 year growth

19%

2 year growth

86%
Simplify Jobs

Simplify's Take

What believers are saying

  • Tango's recent $80 million private placement financing strengthens their financial position and supports ongoing R&D efforts.
  • The company's ability to secure Orphan Drug Designation and Fast Track Designation for their therapies highlights their potential to bring innovative treatments to market quickly.
  • Participation in high-profile investor conferences and scientific meetings enhances Tango's visibility and credibility in the biotech community.

What critics are saying

  • The discontinuation of the TNG348 program due to liver toxicity raises concerns about the safety and viability of their drug candidates.
  • The highly competitive oncology market requires continuous innovation and successful clinical trials to maintain a leading position.

What makes Tango Therapeutics unique

  • Tango Therapeutics leverages the principle of synthetic lethality to develop cancer treatments, a unique approach that specifically targets cancer cells while sparing healthy ones.
  • Their strategic collaborations with larger pharmaceutical companies like Gilead Sciences provide financial support and accelerate the development and commercialization of their therapies.
  • Tango's robust pipeline and focus on precision oncology, including targeting MTAP-deleted solid tumors and BRCA1/2 mutations, set them apart in the oncology market.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE